Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES RIFABUTIN CAPSULES
Authorized Generic of Mycobutin®

PEAPACK, N.J., April 2014 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Rifabutin Capsules to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strength of 150mg x 100.

Greenstone’s Rifabutin Capsules product is the authorized generic of, and equivalent to the innovator’s product, MYCOBUTIN® (rifabutin). This new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the distribution and customer service support of Pfizer Inc., one of the world’s largest pharmaceutical companies. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients it serves.

See the Full Prescribing Information, for Greenstone’s Rifabutin Capsules at http://www.greenstonellc.com/product-list.aspx. For more information about Greenstone LLC and its products, visit http://greenstonellc.com.